Research Analysts Issue Forecasts for Stoke Therapeutics, Inc.’s FY2028 Earnings (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) – HC Wainwright reduced their FY2028 earnings per share estimates for Stoke Therapeutics in a research note issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of $0.17 for the year, down from their prior forecast of $0.18. HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.28) per share.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, March 25th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.02. The firm had revenue of $2.80 million for the quarter, compared to the consensus estimate of $3.70 million.

Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. upped their target price on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 26th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Monday. TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. Wedbush boosted their target price on Stoke Therapeutics from $13.00 to $17.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. Finally, Canaccord Genuity Group dropped their price target on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.57.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $12.01 on Thursday. The stock has a market cap of $625.96 million, a price-to-earnings ratio of -4.98 and a beta of 0.82. Stoke Therapeutics has a 1 year low of $3.35 and a 1 year high of $16.40. The firm’s 50-day moving average is $10.30 and its 200 day moving average is $6.72.

Insider Buying and Selling at Stoke Therapeutics

In other news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the transaction, the chief financial officer now owns 20,746 shares in the company, valued at approximately $126,550.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Stephen J. Tulipano sold 4,116 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the transaction, the chief financial officer now directly owns 20,746 shares in the company, valued at $126,550.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Skorpios Trust sold 3,600,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total value of $41,760,000.00. Following the completion of the transaction, the insider now directly owns 10,843,681 shares in the company, valued at approximately $125,786,699.60. The disclosure for this sale can be found here. Insiders sold a total of 3,622,741 shares of company stock worth $41,935,115 in the last three months. 11.30% of the stock is currently owned by company insiders.

Institutional Trading of Stoke Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of STOK. State Board of Administration of Florida Retirement System purchased a new stake in Stoke Therapeutics in the 1st quarter worth $141,000. Dorsey & Whitney Trust CO LLC purchased a new stake in shares of Stoke Therapeutics during the third quarter worth about $43,000. Sherbrooke Park Advisers LLC bought a new stake in Stoke Therapeutics during the 3rd quarter valued at approximately $48,000. SG Americas Securities LLC purchased a new position in Stoke Therapeutics in the 3rd quarter worth approximately $53,000. Finally, BNP Paribas Financial Markets grew its holdings in Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after buying an additional 6,636 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.